Skip to main content

Table 1 Baseline demographic, clinical characteristics according to cut-off value of fasting triglycerides in the study population

From: Impact of admission triglyceride for early outcome in diabetic patients with stable coronary artery disease

Variables

Total

         Fasting triglycerides

P-value

  

<1.2 mmol/L (N = 103)

≥1.2 mmol/L (N = 226)

 

Demographics

    

  Age, years

59.3 ± 9.3

60.9 ± 9.6

58.7 ± 9.1

0.043

  Male gender

241 (73.3)

77 (74.8)

164 (72.6)

0.677

  Body mass index

25.5 ± 3.0

24.9 ± 3.0

25.7 ± 3.0

0.045

Risk factors

    

  Current Smoking

181 (55.0)

59 (57.3)

122 (54.0)

0.577

  Hypertension

221 (62.1)

64 (62.1)

157 (69.5)

0.189

  Hyperlipidemia

263 (79.9)

76 (73.8)

187 (82.7)

0.060

  Peripheral vascular disease

6 (1.8)

2 (1.9)

4 (1.8)

0.914

  Prior Stroke

13 (4.0)

4 (3.9)

9 (4.0)

0.966

  Family history of CAD

36 (10.9)

10 (9.7)

26 (11.5)

0.628

Angiographic findings

   

0.481

  1-vessel disease

96 (29.2)

30 (29.1)

66 (29.2)

 

  2-vessel disease

80 (24.3)

21 (20.4)

59 (26.1)

 

  3-vessel disease

153 (46.5)

52 (50.5)

101 (44.7)

 

LVEF (%)

62.0 ± 8.3

61.8 ± 8.8

62.1 ± 8.1

0.749

Medical treatment

    

  Aspirin

321 (97.6)

100 (97.1)

221 (97.8)

0.702

  Clopidogrel

315 (95.7)

100 (97.1)

215 (95.1)

0.415

  Beta-blocker

271 (82.7)

79 (76.7)

193 (85.4)

0.053

  ACE-I

85 (25.8)

29 (28.2)

56 (24.8)

0.516

  Statin

320 (97.3)

101 (98.1)

219 (96.9)

0.551

DES implantation

67 (20.4)

22 (21.4)

45 (19.9)

0.762

  1. CAD Coronary artery disease, LV-EF Left ventricular ejection fraction, ACE-I Angiotensin converting enzyme inhibitors, DES Drug eluting stent.